Ralaniten
From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Chemical compound
Pharmaceutical compound
| Clinical data | |
|---|---|
| Other names | EPI-002 |
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C21H27ClO5 |
| Molar mass | 394.89 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed.[1] It is a derivative of bisphenol A [2] and one of the four stereoisomers of EPI-001.[1] A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.[3]
See also
References
- ^ a b Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, et al. (July 2013). "An androgen receptor N-terminal domain antagonist for treating prostate cancer". The Journal of Clinical Investigation. 123 (7): 2948–2960. doi:10.1172/JCI66398. PMC 3696543 . PMID 23722902.
- ^ Monaghan AE, McEwan IJ (2016). "A sting in the tail: the N-terminal domain of the androgen receptor as a drug target". Asian Journal of Andrology. 18 (5): 687–694. doi:10.4103/1008-682X.181081 . PMC 5000789 . PMID 27212126.
- ^ Maughan BL, Antonarakis ES (December 2015). "Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer". Current Treatment Options in Oncology. 16 (12): 57. doi:10.1007/s11864-015-0375-z. PMID 26537882. S2CID 30398927.
Stub icon
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Stub icon
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.